Reg, what do you make of this? Is it the same trial or a different one?
https://pubmed.ncbi.nlm.nih.gov/36602511/Design: Phase IB/IIA randomized control trial.
Settings: Tertiary inflammatory bowel disease referral center.
Patients: Adult Crohn's patients with perianal fistulizing disease.
Intervention: 75 million mesenchymal stem cells were administered with a 22G needle by direct injection after curettage and primary closure of the fistula tract. A repeat injection of 75 million mesenchymal stem cells at 3 months was given if complete clinical and radiographic healing were not achieved.
Main outcomes measures: Adverse and serious adverse events at post procedure day 1, week 2, week 6, month 3, month 6 and month 12. Clinical healing, radiographic healing per magnetic resonance imaging, and patient reported outcomes at the same time points.
Results: A total of 23 patients were enrolled and treated; 18 were treatment and 5 were control. There were no adverse or serious adverse events reported related to mesenchymal stem cells therapy. At six months, 83% of the treatment group and 40% of the control had complete clinical and radiographic healing. The perianal Crohn's disease activity index, Wexner incontinence score, and VanAssche score had all significantly decreased in treatment patients at six months; none significantly decreased in the control group.
Limitations: Single institution and single blinded.
Conclusions: Bone marrow derived mesenchymal stem cells offer a safe and effective alternative treatment approach for severe perianal fistulizing Crohn's disease. See Video Abstract at http://links.lww.com/DCR/C128.
- Forums
- ASX - By Stock
- 2023 Next Steps
Reg, what do you make of this? Is it the same trial or a...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
95.0¢ |
Change
-0.015(1.55%) |
Mkt cap ! $1.084B |
Open | High | Low | Value | Volume |
96.5¢ | 96.5¢ | 94.5¢ | $2.433M | 2.552M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 72431 | 94.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.0¢ | 20225 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 72431 | 0.945 |
6 | 52140 | 0.940 |
8 | 92185 | 0.935 |
5 | 73150 | 0.930 |
4 | 51132 | 0.925 |
Price($) | Vol. | No. |
---|---|---|
0.950 | 20225 | 5 |
0.955 | 42472 | 3 |
0.960 | 80775 | 4 |
0.965 | 57967 | 5 |
0.970 | 73641 | 5 |
Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online